Maraviroc in treatment-experienced patients with HIV-1 infection - experience from routine clinical practice

被引：0
|
作者：
S Reuter
P Braken
B Jensen
S Sierra-Aragon
M Oette
M Balduin
R Kaiser
D Häussinger
机构：
[1] University Hospital,Clinic for Gastroenterology, Hepatology and Infectious Diseases
[2] University Hospital of Cologne,Institute of Virology
[3] Hospital Augustinerinnen,undefined
来源：
European Journal of Medical Research | / 15卷
关键词：
CCR-5; CXCR-4; salvage; genotype; resistance testing;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Duration of antiretroviral regimens in treatment-experienced patients in clinical practice
    Escudero Vilaplana, Vicente
    Plata Paniagua, Sergio
    Trovato Lopez, Nicolas
    Castillo Romera, Isabel
    Ais Larisgoitia, Arantza
    Bellon Cano, Jose Maria
    Sanjurjo Saez, Maria
    [J]. RETROVIROLOGY, 2010, 7 : 64 - 64
  • [32] Efficacy and safety of Maraviroc in treatment-experienced patients. Personal report
    Dell'Isola, C.
    Manzillo, E.
    Aprea, L.
    Franco, A.
    Pizzella, T.
    Simioli, F.
    Izzo, C. M.
    [J]. INFECTION, 2010, 38 : 60 - 60
  • [33] Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Naive and Treatment-Experienced Patients in Canada
    Despiégel N.
    Anger D.
    Martin M.
    Monga N.
    Cui Q.
    Rocchi A.
    Pulgar S.
    Gilchrist K.
    Refoios Camejo R.
    [J]. Infectious Diseases and Therapy, 2015, 4 (3) : 337 - 353
  • [34] Susceptibility of HIV-1 to Tipranavir and Other Antiretroviral Agents in Treatment-Experienced Patients: The UTILIZE Study
    Baxter, John D.
    Bhatti, Laveeza
    Coakley, Eoin
    Bartczak, Jennifer
    McDonough, Marita
    Vinisko, Richard
    Piliero, Peter J.
    [J]. CURRENT HIV RESEARCH, 2010, 8 (04) : 347 - 354
  • [35] Safety and efficacy of rilpivirine-tenofovir-emtricitabine in treatment-experienced patients infected with HIV-1
    Cevik, M.
    Guy, L.
    Sonecha, S.
    Nelson, M.
    [J]. HIV MEDICINE, 2013, 14 : 58 - 58
  • [36] HIV-1 integrase drug-resistance mutations in Iranian treatment-experienced HIV-1-infected patients
    Marjani, Arezoo
    Bokharaei-Salim, Farah
    Jahanbakhshi, Fatemeh
    Monavari, Seyed Hamidreza
    Esghaei, Maryam
    Kalantari, Saeed
    Kiani, Seyed Jalal
    Ataei-Pirkooh, Angila
    Fakhim, Atousa
    Keyvani, Hossein
    [J]. ARCHIVES OF VIROLOGY, 2020, 165 (01) : 115 - 125
  • [37] HIV-1 integrase drug-resistance mutations in Iranian treatment-experienced HIV-1-infected patients
    Arezoo Marjani
    Farah Bokharaei-Salim
    Fatemeh Jahanbakhshi
    Seyed Hamidreza Monavari
    Maryam Esghaei
    Saeed Kalantari
    Seyed Jalal Kiani
    Angila Ataei-Pirkooh
    Atousa Fakhim
    Hossein Keyvani
    [J]. Archives of Virology, 2020, 165 : 115 - 125
  • [38] THE ECONOMIC IMPACT OF MARAVIROC FOR ANTIRETROVIRAL TREATMENT-EXPERIENCED HIV-INFECTED INDIVIDUALS IN MEXICO
    Contreras-Hernandez, I
    Rely, K.
    Mould-Quevedo, J.
    Davila-Loaiza, G.
    [J]. VALUE IN HEALTH, 2009, 12 (03) : A116 - A116
  • [39] Two-Year Safety and Virologic Efficacy of Maraviroc in Treatment-Experienced Patients With CCR5-Tropic HIV-1 Infection: 96-Week Combined Analysis of MOTIVATE 1 and 2
    Hardy, W. David
    Gulick, Roy M.
    Mayer, Howard
    Faetkenheuer, Gerd
    Nelson, Mark
    Heera, Jayvant
    Rajicic, Natasa
    Goodrich, James
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2010, 55 (05) : 558 - 564
  • [40] Population Pharmacokinetic Analysis of Dolutegravir in Treatment-Experienced Adults Living with HIV-1
    Chandasana, Hardik
    Bush, Mark
    Ait-Khaled, Mounir
    Wynne, Brian
    Min, Sherene
    Mehta, Rashmi
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2024,
12345